Clinical Trials on Squamous Cell Carcinoma in Situ in Japan

Total 776 results

Kyowa Kirin, Inc.

Recruiting

A Study of KK2269 in Adult Participants With Solid Tumors

Gastric Adenocarcinoma | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
Chugai Pharmaceutical

Recruiting

A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)

Taiwan, Japan
Takeda

Recruiting

A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice

Ovarian Cancer

Japan
AbbVie

Completed

A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Japan, Korea, Republic of, Taiwan
AstraZeneca

Completed

Iressa 2nd Line Phase III Study in Japan

Non-Small Cell Lung Cancer

Japan
Bayer

Completed

Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients

Thyroid Carcinoma

Japan
Boehringer Ingelheim

Completed

Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Japan
Bristol-Myers Squibb

Recruiting

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer

Netherlands, Belgium, United States, Australia, Greece, Italy, Canada, Japan, Poland, Romania, Spain
Yakult Honsha Co., LTD

Completed

Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

Japan, Korea, Republic of
junya mita

Completed

Poorly Differentiated Adenocarcinoma With Signet Ring Cells of the Gallbladder Producing a High Level of Alpha-fetoprotein: a Case Report

Gallbladder Cancer

Japan
Amgen

Recruiting

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Extensive Stage Small Cell Lung Cancer

Korea, Republic of, United States, Netherlands, Taiwan, Switzerland, Spain, Canada, Israel, Germany, France, Belgium, Australia, Japan, Italy, Denmark
Novartis Pharmaceuticals

Terminated

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Non-Small Cell Lung Cancer

Italy, Singapore, Spain, Germany, Korea, Republic of, United States, Belgium, France, Netherlands, Japan
Eisai Co., Ltd.
Ono Pharmaceutical Co. Ltd

Completed

A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Japan
Boehringer Ingelheim

Completed

Real World Data on Gi(l)Otrif® Dose Adjustment

Carcinoma, Non-Small-Cell Lung

United States, Taiwan, Italy, Singapore, Austria, Canada, France, Germany, Japan, Korea, Republic of, Mexico, Poland, Spain
GlaxoSmithKline

Completed

A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor (PEARL)

Lung Cancer, Non-Small Cell

United States, Estonia, France, Korea, Republic of, United Kingdom, Germany, Japan, Russian Federation, Poland
Pfizer

Completed

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Non-small Cell Lung Cancer With EGFR-Activating Mutations

Italy, Poland, China, Hong Kong, Spain, Korea, Republic of, Japan
Chiba University

Completed

Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy

Bile Duct Cancer

Japan
Cullinan Therapeutics Inc.

Recruiting

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (REZILIENT1)

Non Small Cell Lung Cancer | EGFR Exon 20 Mutation

United States, Taiwan, Spain, Korea, Republic of, Japan, Singapore, Italy, Netherlands, Hong Kong
AstraZeneca
MedImmune LLC

Completed

A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies

Blood Cancer | Advanced B Cell Malignancies

Japan
SymBio Pharmaceuticals

Completed

Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL

Japan
Boehringer Ingelheim

Recruiting

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Lung Cancer, Non-squamous, Non-small Cell

Australia, Korea, Republic of, Spain, China, Japan, United States, Singapore, Hong Kong, United Kingdom, Germany, Taiwan
AstraZeneca

Active, not recruiting

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ORCHARD)

Non-Small Cell Lung Cancer

Denmark, Italy, Spain, United States, Korea, Republic of, Japan, Netherlands, Norway, Sweden
AstraZeneca

Completed

AZD9291 First Time In Patients Ascending Dose Study (AURA)

Advanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung Cancer

United States, France, Germany, Korea, Republic of, Taiwan, United Kingdom, Spain, Italy, Japan, Australia
AstraZeneca

Active, not recruiting

Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

Carcinoma, Non-Small-Cell Lung

Japan
AbbVie

Active, not recruiting

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

Advanced Solid Tumors Cancer | Non Small Cell Lung Cancer (NSCLC)

United States, Australia, France, Israel, Japan, Korea, Republic of, Spain, Taiwan
Bayer

Completed

A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC). (MISSION)

Carcinoma | Non-Small-Cell Lung

Italy, Spain, China, Korea, Republic of, Bulgaria, Turkey, Greece, Philippines, Taiwan, Russian Federation, Hungary, Singapore, France, Netherlands, Sweden, Belgium, United States, Austria, Thailand, Germany, Israel, Poland, Canada, United... and more
Akita University Hospital
Human Genome Center, Institute of Medical Science, University of Tokyo

Suspended

Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer

Bile Duct Cancer

Japan
Taiho Pharmaceutical Co., Ltd.

Terminated

Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma (ORIENTAL)

Hepatocellular Carcinoma

Korea, Republic of, Taiwan, Japan
Novartis Pharmaceuticals

Completed

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Cancer

United States, United Kingdom, Japan, Norway, Spain, Taiwan, France, Germany, Korea, Republic of, Italy, Netherlands
Eli Lilly and Company

Completed

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

Small Cell Lung Cancer

France, Belgium, Spain, United States, Korea, Republic of, Japan, United Kingdom, Turkey
AstraZeneca

Completed

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2)

Carcinoma, Non- Small Cell Lung

United States, Canada, France, Italy, Netherlands, Spain, Belgium, Poland, Taiwan, Vietnam, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Peru, Russian Federation, Hong Kong, Israel, Greece, Australia, Singapore, Turkey, India, A...
Novartis Pharmaceuticals

Terminated

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Advanced Non Small Cell Lung Cancer (NSCLC)

France, Italy, Taiwan, Spain, Netherlands, Japan, Hong Kong, Korea, Republic of, Norway, United States, United Kingdom, Poland
Pfizer

Completed

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001)

Systemic Anaplastic Large-Cell Lymphoma | Non-Small Cell Lung Cancer ALK-positive | Non-Small Cell Lung Cancer c-Met Dependent | Non-Small Cell Lung Cancer ROS Marker Positive | Advanced Malignancies Except Leukemia

United States, Korea, Republic of, Australia, Japan
Chugai Pharmaceutical
Japan Lung Cancer Society

Completed

A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)

Non-small-Cell Lung Cancer

Japan
Haruhiko Fukuda
Ministry of Health, Labour and Welfare, Japan

Completed

A Phase II Study of Stereotactic Body Radiation Therapy in Patients With T1N0M0 Non-small Cell Lung Cancer (JCOG0403)

T1N0M0 Non-small Cell Lung Cancer

Japan
Takeda

Completed

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

ALK-positive Advanced NSCLC

Japan
Daiichi Sankyo Co., Ltd.
AstraZeneca; Daiichi Sankyo, Inc.

Recruiting

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Hormone Receptor Positive Breast Cancer

United States, Japan
Janssen Research & Development, LLC

Active, not recruiting

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS)

Non-Small-Cell Lung Cancer

United States, France, Taiwan, United Kingdom, China, Spain, Japan, Australia, Korea, Republic of, Canada
Daiichi Sankyo
Merck Sharp & Dohme LLC

Active, not recruiting

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung01)

Extensive-stage Small-cell Lung Cancer

United States, Germany, Spain, China, Korea, Republic of, France, Taiwan, Japan
AstraZeneca

Completed

A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone (IMPRESS)

Non-Small Cell Lung Cancer

Italy, Spain, France, Korea, Republic of, Hungary, Japan, China, Taiwan, Hong Kong, Germany, Russian Federation
National Cancer Center Hospital East
Daiichi Sankyo Co., Ltd.

Recruiting

Phase 2 Study of T-DXd in the Neoadjuvant Treatment for Patients With HER2 Positive Gastric and GEJ Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
SFJ Pharma Ltd. II
Pfizer; SFJ Pharmaceuticals, Inc.

Terminated

Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients (ATLAS)

Clear Cell Renal Carcinoma

France, China, Hong Kong, Taiwan, Spain, United States, India, Korea, Republic of, Japan
Pfizer

Completed

A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)

Carcinoma, Hepatocellular

Japan
Boehringer Ingelheim

Recruiting

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Small Cell Lung Carcinoma | Neuroendocrine Neoplasms

United States, Belgium, Spain, Korea, Republic of, United Kingdom, Germany, Japan, China, Taiwan, France, Portugal, Bulgaria
AstraZeneca

Active, not recruiting

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) (CASPIAN)

Small Cell Lung Carcinoma Extensive Disease

Germany, United States, Poland, Taiwan, Turkey, Italy, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Russian Federation, China, Netherlands, Spain, Israel, Ukraine, Austria, France, Bulgaria, Romania, Argentina, Slovakia
AstraZeneca
Japan Lung Cancer Society

Completed

Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC (AYAME)

Carcinoma, Non-Small-Cell Lung

Japan
AstraZeneca

Completed

First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia (IPASS)

Non-Small Cell Lung Cancer

Philippines, China, Malaysia, Japan, Hong Kong, Taiwan, Thailand, Indonesia, Singapore
Amgen

Recruiting

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) (DeLLphi-306)

Small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer

China, Japan, United States, Taiwan, Australia, Turkey, Korea, Republic of
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Cemiplimab in Adults With Cervical Cancer

Squamous Cell Carcinoma (SCC) | Recurrent or Metastatic, Platinum-refractory Cervical Cancer

Spain, Korea, Republic of, United States, United Kingdom, Taiwan, Brazil, Belgium, Australia, Italy, Canada, Japan, Greece, Poland, Russian Federation
Hoffmann-La Roche

Active, not recruiting

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Non-Small-Cell Lung

United States, Korea, Republic of, United Kingdom, Australia, France, Italy, Spain, Japan, Brazil, China, Germany, Poland, Thailand, Israel, Switzerland, Taiwan, Austria, Russian Federation, Ukraine, Hungary, Serbia, Slovenia, South... and more

Clinical Trials on Squamous Cell Carcinoma in Situ in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations